[
  {
    "id": "mucinous-pancreatic-tumor-overview_44388_1750166974.txt-1",
    "source_document": "mucinous-pancreatic-tumor-overview_44388_1750166974.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Definition / general",
    "url": "https://www.pathologyoutlines.com/topic/pancreasmucin.html#definitiongeneral451991",
    "clean_content": "Definition / general\n\n* Neoplasms within the pancreas characterized by predominant mucin\n  production by the tumor cells* Mucus: a substance that is 95 - 98% water and 2 - 5% solids, with > 60% of\n    the solid component consisting of mucin ([World J Gastroenterol 2011;17:4757](22147976))* [Mucin](https://www.pathologyoutlines.com/topic/stainsmucins.html): a glycoprotein consisting of a polypeptide backbone with attached\n      oligosaccharide conjugates"
  },
  {
    "id": "mucinous-pancreatic-tumor-overview_44388_1750166974.txt-2",
    "source_document": "mucinous-pancreatic-tumor-overview_44388_1750166974.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Essential features",
    "url": "https://www.pathologyoutlines.com/topic/pancreasmucin.html#essentialfeatures451992",
    "clean_content": "Essential features\n\n* General term for benign, low or high grade dysplastic or malignant\n  mucin producing epithelium within the pancreas* 4 most prevalent types\n    1. [Simple mucinous cyst / mucinous nonneoplastic cyst (MNC)](https://www.pathologyoutlines.com/topic/pancreasmucnoncyst.html)* [Mucinous cystic neoplasm (MCN)](https://www.pathologyoutlines.com/topic/pancreasmcn.html)* [Intraductal papillary mucinous neoplasm (IPMN)](https://www.pathologyoutlines.com/topic/pancreasipmn.html)* [Mucin producing pancreatic ductal adenocarcinoma](https://www.pathologyoutlines.com/topic/pancreasductal.html)* MCN and IPMN may harbor or develop into pancreatic ductal adenocarcinoma (small percentage); MCN may undergo transformation to cystadenocarcinoma as well ([Pancreas 2017;46:745](28609361))\n\n  \n  \n\n\nComparison of essential features of the 4 types of pancreatic mucinous tumors\n\n|  | Simple mucinous cyst / MNC | MCN | IPMN | Pancreatic ductal adenocarcinoma |\n **Age, decade** | Sixth - seventh | Fourth - fifth | Sixth - seventh | Sixth - eighth || **Location** | Head = body = tail | Body / tail > head | Head > body / tail | Head > body / tail |\n| **Sex predilection** | F > M | F >>> M | Main duct: M > F   Branch duct: F > M | M > F |\n| **CEA** | ↑ | ↑ | ↑ | N / A |\n| **Amylase** | ↓ | ↓ | ↑ | N / A |\n| **Pancreatic duct communication** | Rare | No | Yes | Yes |\n| **Precursor for invasive carcinoma** | No | Yes | Yes | N / A |\n| **Cytologic atypia** | No | Low grade / high grade | Low grade / high grade | N / A |\n| **Epithelium type** | Flat | Flat or papillary | Papillary | Flat or papillary |\n| **Ovarian stroma** | No | Yes | No | N / A |\n| **Molecular mutations** | *KMT2C*, *KRAS*, *BRAF*, *RNF43*, *CDKN2A*, *TP53*, *SMAD4* | *KRAS*, *RNF43* (low grade); *SMAD4*, *TP53* (high grade) | *GNAS*, *KRAS*, *RNF43*, *TP53* | *KRAS, TP53, CDKN2A,  SMAD4, BRCA1/2* |"
  },
  {
    "id": "mucinous-pancreatic-tumor-overview_44388_1750166974.txt-3",
    "source_document": "mucinous-pancreatic-tumor-overview_44388_1750166974.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Terminology",
    "url": "https://www.pathologyoutlines.com/topic/pancreasmucin.html#terminology451993",
    "clean_content": "Terminology\n\n* Simple mucinous cyst / mucinous nonneoplastic cyst* Mucinous cystic neoplasm / mucinous cystadenoma* Intraductal papillary mucinous neoplasm / carcinoma in situ* Pancreatic ductal adenocarcinoma / duct cell adenocarcinoma / infiltrating duct carcinoma / tubular adenocarcinoma"
  },
  {
    "id": "mucinous-pancreatic-tumor-overview_44388_1750166974.txt-4",
    "source_document": "mucinous-pancreatic-tumor-overview_44388_1750166974.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "ICD coding",
    "url": "https://www.pathologyoutlines.com/topic/pancreasmucin.html#icdcoding451994",
    "clean_content": "ICD coding\n\n* See individual topics\n  + [Simple mucinous cyst / mucinous nonneoplastic cyst (MNC)](https://www.pathologyoutlines.com/topic/pancreasmucnoncyst.html)+ [Mucinous cystic neoplasm (MCN)](https://www.pathologyoutlines.com/topic/pancreasmcn.html)+ [Intraductal papillary mucinous neoplasm (IPMN)](https://www.pathologyoutlines.com/topic/pancreasipmn.html)+ [Pancreatic ductal adenocarcinoma](https://www.pathologyoutlines.com/topic/pancreasductal.html)"
  },
  {
    "id": "mucinous-pancreatic-tumor-overview_44388_1750166974.txt-5",
    "source_document": "mucinous-pancreatic-tumor-overview_44388_1750166974.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Epidemiology",
    "url": "https://www.pathologyoutlines.com/topic/pancreasmucin.html#epidemiology451995",
    "clean_content": "Epidemiology\n\n* Simple mucinous cyst / mucinous nonneoplastic cyst (MNC)\n  + 2 - 7% of pancreatic cyst resections and 8 - 10% of mucinous cysts of the pancreas+ More common in women (F:M = 2.8:1), mean age of 64 years old ([Arch Pathol Lab Med 2017;141:1330](28968161))* Mucinous cystic neoplasm (MCN)\n    + Comprises ~25% of resected pancreatic cystic neoplasms+ Almost exclusively in women (> 95%)+ Rare; 2 - 5% exocrine pancreatic tumors+ Most common in fourth through fifth decade ([Arch Pathol Lab Med 2017;141:1330](28968161), [Gut Liver 2015;9:571](26343068))* Intraductal papillary mucinous neoplasm (IPMN)\n      + May account for between 18 and 50% of resected cystic pancreatic lesions ([Arch Surg 2009;144:448](19451487), [Pancreas 2008;37:254](18815545), [Pancreas 2011;40:779](21673537))+ Main duct IPMN is slightly more common in men (M:F = 1.1:1), while branch duct IPMN is more common in women (M:F = 0.76:1) ([Diagnostics (Basel) 2022;13:65](36611356))+ Most common in sixth through seventh decade ([Arch Pathol Lab Med 2017;141:1330](28968161))* Pancreatic ductal adenocarcinoma\n        + Most common pancreatic tumor (~90% of pancreatic cancer diagnoses)+ 80% occur in patients 60 - 80 years old+ Slightly more common in men ([CA Cancer J Clin 2018;68:394](30207593))+ Colloid carcinoma / mucinous carcinoma is an uncommon variant with > 50% extracellular mucus production, accounting for 1 - 3%"
  },
  {
    "id": "mucinous-pancreatic-tumor-overview_44388_1750166974.txt-6",
    "source_document": "mucinous-pancreatic-tumor-overview_44388_1750166974.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Sites",
    "url": "https://www.pathologyoutlines.com/topic/pancreasmucin.html#sites451996",
    "clean_content": "Sites\n\n* Simple mucinous cyst / mucinous nonneoplastic cyst (MNC)\n  + Occur equally in head / neck / uncinate and body / tail ([Arch Pathol Lab Med 2017;141:1330](28968161))* Mucinous cystic neoplasm (MCN)\n    + > 95% arise in the distal pancreas as a single lesion ([Gut Liver 2015;9:571](26343068))* Intraductal papillary mucinous neoplasm (IPMN)\n      + Can occur anywhere in the pancreas, most common in the head (~58%) ([Am J Clin Pathol 2020;154:559](32589187))* Pancreatic ductal adenocarcinoma\n        + 60 - 70% occur in pancreatic head\n        + Usually solitary, occasionally multifocal ([Surg Pathol Clin 2016;9:547](27926359))"
  },
  {
    "id": "mucinous-pancreatic-tumor-overview_44388_1750166974.txt-7",
    "source_document": "mucinous-pancreatic-tumor-overview_44388_1750166974.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Pathophysiology",
    "url": "https://www.pathologyoutlines.com/topic/pancreasmucin.html#pathophysiology451997",
    "clean_content": "Pathophysiology\n\n* Simple mucinous cyst / mucinous nonneoplastic cyst (MNC)\n  + Unknown pathogenesis but may develop from acinar ductal mucinous metaplasia ([Hum Pathol 2010;41:513](19954814), [Arch Pathol Lab Med 2017;141:1330](28968161))* Mucinous cystic neoplasm (MCN)\n    + Stromal component possibly derived from ovarian primordium / Müllerian type stroma or primary yolk cells implanted in the pancreas during embryogenesis ([Am J Surg Pathol 1999;23:410](10199470), [Dig Surg 2006;23:186](16837797))* Intraductal papillary mucinous neoplasm (IPMN)\n      + Histologically arising in the pancreatic main duct, branch duct or combined ([Clin Gastroenterol Hepatol 2010;8:213](19835989))* Pancreatic ductal adenocarcinoma\n        + Arises from pancreatic duct epithelia+ Precursor lesions include intraductal papillary mucinous neoplasm (IPMN), mucinous cystic neoplasm (MCN) and pancreatic intraepithelial neoplasia (PanIN)"
  },
  {
    "id": "mucinous-pancreatic-tumor-overview_44388_1750166974.txt-8",
    "source_document": "mucinous-pancreatic-tumor-overview_44388_1750166974.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Etiology",
    "url": "https://www.pathologyoutlines.com/topic/pancreasmucin.html#etiology451998",
    "clean_content": "Etiology\n\n* Simple mucinous cyst / mucinous nonneoplastic cyst (MNC)\n  + Unclear etiology* Mucinous cystic neoplasm (MCN)\n    + No known etiology* Intraductal papillary mucinous neoplasm (IPMN)\n      + In one study, most patients with IPMN were cigarette smokers ([Adv Anat Pathol 1999;6:65](10331069))+ Patients with Peutz-Jeghers syndrome, familial adenomatous polyposis and McCune-Albright syndrome are at increased risk ([Adv Anat Pathol 1999;6:65](10331069), [Gut 2002;51:446](12171972), [Virchows Arch 2017;470:391](28188442))* Pancreatic ductal adenocarcinoma\n        + Strongly associated with cigarette smoking (2 - 3x increased risk)+ History of pancreatitis (2 - 10 fold increased risk)+ Obesity / diet (risk increases with increasing body mass index [BMI])+ Hereditary pancreatic cancer syndrome (due to an underlying germline mutation)+ Familial pancreatic cancer syndrome (defined as pancreatic cancer in at least 2 first degree relatives without an underlying germline mutation)+ Other possible factors: high alcohol consumption, previous gastric surgery and diabetes ([Lancet Gastroenterol Hepatol 2016;1:298](28404200), [Lancet Gastroenterol Hepatol 2016;1:226](28404095), [Medicine (Baltimore) 2017;96:e5908](28099352))"
  },
  {
    "id": "mucinous-pancreatic-tumor-overview_44388_1750166974.txt-9",
    "source_document": "mucinous-pancreatic-tumor-overview_44388_1750166974.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Clinical features",
    "url": "https://www.pathologyoutlines.com/topic/pancreasmucin.html#clinicalfeatures452000",
    "clean_content": "Clinical features\n\n* Simple mucinous cyst / mucinous nonneoplastic cyst (MNC)\n  + Half of patients are asymptomatic; others report abdominal pain or\n    jaundice ([Arch Pathol Lab Med 2017;141:1330](28968161))* Mucinous cystic neoplasm (MCN)\n    + More than half of patients are asymptomatic+ Causes compression of adjacent structures+ Symptoms include a palpable mass in the epigastric region and nonspecific abdominal pain or distension ([World J Gastrointest Oncol 2020;12:642](32699579))* Intraductal papillary mucinous neoplasm (IPMN)\n      + Majority are asymptomatic; often incidental+ Symptoms present in 2 - 20% of patients and include epigastric pain, weight loss, diabetes and jaundice ([Gut Liver 2015;9:571](26343068), [Arch Pathol Lab Med 2022;146:298](35192699))* Pancreatic ductal adenocarcinoma\n        + Most commonly reported symptoms: loss of appetite (~45%), jaundice (~41%) and abdominal pain (40%)+ Other symptoms include weight loss, back pain, new onset diabetes, depression, migratory thrombophlebitis and acute pancreatitis ([Clin Gastroenterol Hepatol 2004;2:510](15181621))"
  },
  {
    "id": "mucinous-pancreatic-tumor-overview_44388_1750166974.txt-10",
    "source_document": "mucinous-pancreatic-tumor-overview_44388_1750166974.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Diagnosis",
    "url": "https://www.pathologyoutlines.com/topic/pancreasmucin.html#diagnosis452001",
    "clean_content": "Diagnosis\n\n* Overall, diagnosis of mucinous cysts and neoplasms of the pancreas relies on\n  + Cyst fluid analysis obtained from endoscopic ultrasound guided fine needle aspiration (EUS FNA)+ Cytology analysis (EUS FNA)+ Histologic analysis of surgical resection* Reference: [Front Physiol 2022;13:856803](35309060)"
  },
  {
    "id": "mucinous-pancreatic-tumor-overview_44388_1750166974.txt-11",
    "source_document": "mucinous-pancreatic-tumor-overview_44388_1750166974.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Laboratory",
    "url": "https://www.pathologyoutlines.com/topic/pancreasmucin.html#laboratory452002",
    "clean_content": "Laboratory\n\n* Simple mucinous cyst / mucinous nonneoplastic cyst (MNC)\n  + Cyst fluid often shows variably elevated carcinoembryonic antigen (CEA) and amylase* Mucinous cystic neoplasm (MCN)\n    + Serum tumor markers include CEA, CA 19-9, TAG-72, CA 15-3 or MCA and low levels of amylase+ Cyst fluid often shows elevated CEA, CA 19-9 and low amylase* Intraductal papillary mucinous neoplasm (IPMN)\n      + Serum amylase and lipase are elevated+ Cyst fluid shows elevated CEA and amylase* Pancreatic ductal adenocarcinoma\n        + Serum tumor markers include CA 19-9, CEA+ Cyst fluid has high levels of CA 19-9, DUPAN-2, CEA, Span-1\n            ([Arch Pathol Lab Med 2017;141:1330](28968161), [Front Physiol 2022;13:856803](35309060))"
  },
  {
    "id": "mucinous-pancreatic-tumor-overview_44388_1750166974.txt-12",
    "source_document": "mucinous-pancreatic-tumor-overview_44388_1750166974.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Radiology description",
    "url": "https://www.pathologyoutlines.com/topic/pancreasmucin.html#radiologydescription452003",
    "clean_content": "Radiology description\n\n* Simple mucinous cyst / mucinous nonneoplastic cyst (MNC)\n  + Single unilocular or multilocular cyst ([Front Physiol 2022;13:856803](35309060))* Mucinous cystic neoplasm (MCN)\n    + Well defined multilocular or unilocular thick walled cyst+ No connection with the main pancreatic duct ([Front Physiol 2022;13:856803](35309060))* Intraductal papillary mucinous neoplasm (IPMN)\n      + Dilated main pancreatic duct in main duct type IPMN+ Branch duct IPMN typically produces a grape-like cyst+ Mural nodules may correspond to high grade dysplasia ([Front Physiol 2022;13:856803](35309060))* Pancreatic ductal adenocarcinoma\n        + Irregular, solid hypodense mass+ Double duct sign (dilation of both the biliary and pancreatic ducts) is pathognomonic ([Radiology 2011;260:446](21693662))"
  },
  {
    "id": "mucinous-pancreatic-tumor-overview_44388_1750166974.txt-13",
    "source_document": "mucinous-pancreatic-tumor-overview_44388_1750166974.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Prognostic factors",
    "url": "https://www.pathologyoutlines.com/topic/pancreasmucin.html#prognosticfactors452005",
    "clean_content": "Prognostic factors\n\n* Simple mucinous cyst / mucinous nonneoplastic cyst (MNC)\n  + Not associated with progression or invasive carcinoma ([Arch Pathol Lab Med 2017;141:1330](28968161))* Mucinous cystic neoplasm (MCN)\n    + 5 year survival rate of 96 - 100% after surgical resection ([Am J Surg Pathol 2015;39:179](25517958), [World J Surg Oncol 2020;18:287](33148260))+ No survival difference between MCNs with low grade or high grade dysplasia ([Am J Surg Pathol 2018;42:578](29462092))+ Invasion limited to the ovarian type stroma, cystic septa or capsule has a favorable outcome (5 year survival 100%), while extracapsular invasion is associated with poor survival ([J Pathol Clin Res 2021;7:507](34062050))* Intraductal papillary mucinous neoplasm (IPMN)\n      + Absence of invasive carcinoma is the most important prognostic factor ([Hum Pathol 2012;43:1](21777948))+ Main duct type shows highest incidence of invasive adenocarcinoma (30 - 50%)+ Branch type without mural nodules are more commonly found with low grade dysplasia (~24% with invasion) ([Dig Liver Dis 2012;44:257](22030480), [Am J Surg Pathol 2000;24:1372](11023098), [Arch Pathol Lab Med 2022;146:298](35192699))* Pancreatic ductal adenocarcinoma\n        + Most ductal adenocarcinomas are fatal (5 year survival ~5%)+ Survival time is longer in patients with tumors confined to the pancreas or < 3 cm in diameter+ Tumors in the body or tail tend to present at a more advanced stage ([Cancer Res 2014;74:2913](24840647), [J Gastrointest Surg 2000;4:567](11307091))+ Colloid carcinomas have a better prognosis than conventional adenocarcinomas with a 5 year survival rate of > 55% ([Am J Surg Pathol 2003;27:571](12717243))"
  },
  {
    "id": "mucinous-pancreatic-tumor-overview_44388_1750166974.txt-14",
    "source_document": "mucinous-pancreatic-tumor-overview_44388_1750166974.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Case reports",
    "url": "https://www.pathologyoutlines.com/topic/pancreasmucin.html#casereports452006",
    "clean_content": "Case reports\n\n* 32 year old woman with a large mucinous cystic neoplasm of the pancreas arising during pregnancy ([J Surg Case Rep 2020;2020:rjaa085](32665837))* 63 year old man with a 2 year history of abdominal pain without weight loss and a simple mucinous cyst ([Virchows Arch 2021;479:179](33511431))* 72 year old woman with pancreatic ductal carcinoma arising in pancreatic remnant 13 years after resected IPMN ([Mol Clin Oncol 2018;8:417](29456847))* 78 year old woman with a bowel obstruction and an intraductal papillary mucinous neoplasm ([Radiol Case Rep 2023;18:1103](36684624))* 91 year old woman with new onset diabetes mellitus and a pancreatic ductal adenocarcinoma ([Cureus 2022;14:e31608](36540459))"
  },
  {
    "id": "mucinous-pancreatic-tumor-overview_44388_1750166974.txt-15",
    "source_document": "mucinous-pancreatic-tumor-overview_44388_1750166974.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Treatment",
    "url": "https://www.pathologyoutlines.com/topic/pancreasmucin.html#treatment452007",
    "clean_content": "Treatment\n\n* Simple mucinous cyst / mucinous nonneoplastic cyst (MNC)\n  + Typically resected, may be treated conservatively with continued imaging follow up* Mucinous cystic neoplasm (MCN)\n    + Surgical resection is typical+ Can follow with close imaging surveillance for poor surgical candidates with MCN without high risk imaging findings ([Gut Liver 2015;9:571](26343068))* Intraductal papillary mucinous neoplasm (IPMN)\n      + Surgical resection for main duct IPMNs+ Can follow with close imaging surveillance for branch duct IPMN < 3 cm without high risk imaging findings ([Arch Pathol Lab Med 2022;146:298](35192699))* Pancreatic ductal adenocarcinoma\n        + Radical resection with or without chemotherapy"
  },
  {
    "id": "mucinous-pancreatic-tumor-overview_44388_1750166974.txt-16",
    "source_document": "mucinous-pancreatic-tumor-overview_44388_1750166974.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Gross description",
    "url": "https://www.pathologyoutlines.com/topic/pancreasmucin.html#grossdescription452009",
    "clean_content": "Gross description\n\n* Simple mucinous cyst / mucinous nonneoplastic cyst (MNC)\n  + Macroscopic cyst > 1 cm, usually 3 - 12 cm+ Unilocular or multilocular+ May contain clear, serous or mucinous fluid ([Arch Pathol Lab Med 2017;141:1330](28968161))* Mucinous cystic neoplasm (MCN)\n    + 2 - 35 cm in greatest dimension+ Unilocular or multilocular, thick walls+ Round mass with smooth surface and fibrous pseudocapsule, can have papillary projections in higher grade lesions+ Calcifications may be present+ May contain thick mucin, hemorrhage or necrotic debris ([Am J Surg Pathol 2015;39:179](25517958))* Intraductal papillary mucinous neoplasm (IPMN)\n      + 1 - 8 cm in greatest dimension+ Cystic, multiloculated+ Grape-like clusters in branch type* Pancreatic ductal adenocarcinoma\n        + Firm, poorly defined mass, with yellow to white cut surface+ Can be difficult to differentiate from background pancreatitis ([HPB (Oxford) 2014;16:83](23472829))"
  },
  {
    "id": "mucinous-pancreatic-tumor-overview_44388_1750166974.txt-17",
    "source_document": "mucinous-pancreatic-tumor-overview_44388_1750166974.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Gross images",
    "url": "https://www.pathologyoutlines.com/topic/pancreasmucin.html#grossimages452010",
    "clean_content": "Gross images\n\n*Contributed by Katrina Krogh, M.D.*  \n\n[![PDA: ill defined white lesion](https://www.pathologyoutlines.com/imgau/pancreasmucinKrogh02new.jpg)](https://www.pathologyoutlines.com/imgau/pancreasmucinKrogh02new.jpg)\n\nPDA: ill defined white lesion\n\n[![MCN: unilocular cyst with thick wall](https://www.pathologyoutlines.com/imgau/pancreasmucinKrogh03new.jpg)](https://www.pathologyoutlines.com/imgau/pancreasmucinKrogh03new.jpg)\n\nMCN: unilocular cyst with thick wall\n\n[![IPMN: small cysts with smooth linings](https://www.pathologyoutlines.com/imgau/pancreasmucinKrogh001new.jpg)](https://www.pathologyoutlines.com/imgau/pancreasmucinKrogh001new.jpg)\n\nIPMN: small cysts with smooth linings\n\n[![MNC: unilocular simple cyst with smooth thin lining](https://www.pathologyoutlines.com/imgau/pancreasmucinKrogh04nnew.jpg)](https://www.pathologyoutlines.com/imgau/pancreasmucinKrogh04nnew.jpg)\n\nMNC: unilocular  \n simple cyst with  \n smooth thin lining"
  },
  {
    "id": "mucinous-pancreatic-tumor-overview_44388_1750166974.txt-18",
    "source_document": "mucinous-pancreatic-tumor-overview_44388_1750166974.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Microscopic (histologic) description",
    "url": "https://www.pathologyoutlines.com/topic/pancreasmucin.html#microscopichistologicdescription452013",
    "clean_content": "Microscopic (histologic) description\n\n* Simple mucinous cyst / mucinous nonneoplastic cyst (MNC)\n  + Cyst lined by monolayer of cuboidal to columnar mucinous epithelium+ Usually has gastric phenotype+ No ovarian type stroma present+ Little to no cytologic atypia and no / minimal papillary excrescences in epithelial lining+ No malignant potential+ Rare cases of focal high grade dysplasia reported ([Arch Pathol Lab Med 2017;141:1330](28968161))* Mucinous cystic neoplasm (MCN)\n    + Cyst lined by 2 components\n      - Inner epithelial layer composed predominantly of mucin producing cells- Outer densely cellular Müllerian / ovarian type stroma+ No connection to ducts+ Stroma can undergo luteinization, can have hilar-like cells and immunophenotypic sex cord stromal differentiation+ 2 tiered grading system\n            - Low grade: mild moderate atypia, mitoses and papillary projections uncommon- High grade: severe atypia, papillae formation with irregular branching, loss of nuclear polarity, frequent mitoses+ Invasion seen in ~16% of MCN ([Arch Pathol Lab Med 2022;146:298](35192699))* Intraductal papillary mucinous neoplasm (IPMN)\n      + Cyst lined by neoplastic columnar / mucinous epithelium that can be flat or form papillae+ 3 types of epithelium\n          - Intestinal type (~20%): resembles villous adenomas of the gastrointestinal tract; often contains high grade dysplasia- Gastric type (~70%): resembles gastric foveolar epithelium; often low grade dysplasia- Pancreatobiliary type (~10%): frequently involves the main duct, shows complex branching of papillae and often contains high grade dysplasia+ 2 tiered grading system\n            - Low grade: mild moderate atypia, mitoses are uncommon- High grade: severe atypia, irregular branching and budding of papillae, loss of nuclear polarity, frequent mitoses ([Arch Pathol Lab Med 2022;146:298](35192699))* Pancreatic ductal adenocarcinoma\n        + Classically shows well developed neoplastic glands that imitate normal pancreatic ducts in the background of desmoplastic stroma+ Neoplastic glands show an irregular and haphazard distribution with irregular contours and frequently contain neutrophils and necrotic debris+ Nuclear pleomorphism, prominent nucleoli and mitoses are typically frequent+ Mucin containing glands may be ruptured or poorly formed+ Most are well to moderately differentiated+ Grade (College of American Pathologists) based on extent of glandular differentiation\n                    - Well differentiated (> 95% of tumor composed of glands)- Moderately differentiated (50 - 95% of tumor composed of glands)- Poorly differentiated (≤ 49% of tumor composed of glands)+ Colloid carcinoma is a subtype that contains ≥ 80% of neoplastic cells suspended in pools of mucin"
  },
  {
    "id": "mucinous-pancreatic-tumor-overview_44388_1750166974.txt-19",
    "source_document": "mucinous-pancreatic-tumor-overview_44388_1750166974.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Microscopic (histologic) images",
    "url": "https://www.pathologyoutlines.com/topic/pancreasmucin.html#microscopichistologicimages452014",
    "clean_content": "Microscopic (histologic) images\n\n*Contributed by Jen Rytych, M.D. and Katrina Krogh, M.D.*  \n\n[![Mucinous pancreatic adenocarcinoma](https://www.pathologyoutlines.com/imgau/pancreasmucinRytych01.jpg)](https://www.pathologyoutlines.com/imgau/pancreasmucinRytych01.jpg)\n\nMucinous pancreatic adenocarcinoma\n\n[![Pancreatic adenocarcinoma, grade 2](https://www.pathologyoutlines.com/imgau/pancreasmucinKrogh24new.jpg)](https://www.pathologyoutlines.com/imgau/pancreasmucinKrogh24new.jpg)\n\nPancreatic adenocarcinoma, grade 2\n\n[![MCN: ovarian type stroma](https://www.pathologyoutlines.com/imgau/pancreasmucinKrogh08nnew.jpg)](https://www.pathologyoutlines.com/imgau/pancreasmucinKrogh08nnew.jpg)\n\nMCN: ovarian type stroma\n\n[![IPMN, gastric type](https://www.pathologyoutlines.com/imgau/pancreasmucinKrogh21nnew.jpg)](https://www.pathologyoutlines.com/imgau/pancreasmucinKrogh21nnew.jpg)\n\nIPMN, gastric type\n\n[![IPMN, intestinal type](https://www.pathologyoutlines.com/imgau/pancreasmucinKrogh20new.jpg)](https://www.pathologyoutlines.com/imgau/pancreasmucinKrogh20new.jpg)\n\nIPMN, intestinal type\n\n[![Simple mucinous cyst / mucinous nonneoplastic cyst (MNC)](https://www.pathologyoutlines.com/imgau/pancreasmucinKrogh22new.jpg)](https://www.pathologyoutlines.com/imgau/pancreasmucinKrogh22new.jpg)\n\nMNC"
  },
  {
    "id": "mucinous-pancreatic-tumor-overview_44388_1750166974.txt-20",
    "source_document": "mucinous-pancreatic-tumor-overview_44388_1750166974.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Cytology description",
    "url": "https://www.pathologyoutlines.com/topic/pancreasmucin.html#cytologydescription452016",
    "clean_content": "Cytology description\n\n* Simple mucinous cyst / mucinous nonneoplastic cyst (MNC)\n  + Cuboidal or columnar cells in strips or honeycomb sheets without significant atypia+ Background mucin and macrophages are frequently present ([Pancreas 2013;42:27](22750967))* Mucinous cystic neoplasm (MCN)\n    + Cannot be distinguished from IPMN on cytology+ Low grade MCN will have low cellularity with a variable amount of mucin with histiocytes and bland epithelial cells+ High grade MCN will have low to moderate cellularity, variable amount of mucin, pleomorphic, atypical cells with a high nuclear to cytoplasmic ratio and frequent necrosis+ Ovarian type stroma is not typically present ([Cancer Cytopathol 2017;125:169](27926784))* Intraductal papillary mucinous neoplasm (IPMN)\n      + Cannot be distinguished from MCN on cytology+ Low grade IPMN will have low cellularity with minimal nuclear atypia in epithelial cells and no background necrosis+ High grade IPMN will be more cellular with small epithelial cells with hyperchromatic, irregular nuclei and prominent background inflammation and necrosis in most cases ([Cancer Cytopathol 2014;122:40](23939829))* Pancreatic ductal adenocarcinoma\n        + Typically highly cellular, often with background necrosis+ Tissue fragments are composed of cells with irregular nuclear spacing (drunken honeycomb), hyperchromatic nuclei with irregular contours and occasional atypical mitotic figures ([Cancer 2003;99:44](12589645))"
  },
  {
    "id": "mucinous-pancreatic-tumor-overview_44388_1750166974.txt-21",
    "source_document": "mucinous-pancreatic-tumor-overview_44388_1750166974.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Positive stains",
    "url": "https://www.pathologyoutlines.com/topic/pancreasmucin.html#positivestains452020",
    "clean_content": "Positive stains\n\n* **[Simple mucinous cyst / mucinous nonneoplastic cyst (MNC)](https://www.pathologyoutlines.com/topic/pancreasmucnoncyst.html)**\n  + Cytokeratins ([7](https://www.pathologyoutlines.com/topic/stainsck7.html),\n    [8](https://www.pathologyoutlines.com/topic/stainsck8.html),\n    [18](https://www.pathologyoutlines.com/topic/stainsck18.html),\n    [19](https://www.pathologyoutlines.com/topic/stainsck19.html),\n    [20](https://www.pathologyoutlines.com/topic/stainsck20.html)),\n    [CA 19-9](https://www.pathologyoutlines.com/topic/stainsca19-9.html),\n    [MUC5AC](https://www.pathologyoutlines.com/topic/stainsmuc2.html#muc5ac) (90%),\n    [MUC6](https://www.pathologyoutlines.com/topic/stainsmuc2.html#muc6) (74%) ([Arch Pathol Lab Med 2017;141:1330](28968161))* [Mucinous cystic neoplasm (MCN)](https://www.pathologyoutlines.com/topic/pancreasmcn.html)\n    + Epithelial component: [CEA](https://www.pathologyoutlines.com/topic/stainscea.html), cytokeratins ([7](https://www.pathologyoutlines.com/topic/stainsck7.html), [8](https://www.pathologyoutlines.com/topic/stainsck8.html),\n      [18](https://www.pathologyoutlines.com/topic/stainsck18.html) and [19](https://www.pathologyoutlines.com/topic/stainsck19.html)) ([Gut Liver 2015;9:571](26343068))+ Stromal component: [vimentin](https://www.pathologyoutlines.com/topic/stainsvimentin.html),\n        [alpha SMA](https://www.pathologyoutlines.com/topic/stainsalphasmoothmuscleactin.html),\n        [desmin](https://www.pathologyoutlines.com/topic/stainsdesmin.html),\n        [inhibin](https://www.pathologyoutlines.com/topic/stainsinhibina.html),\n        [ER](https://www.pathologyoutlines.com/topic/stainser.html),\n        [PR](https://www.pathologyoutlines.com/topic/stainsprog.html) and [CD10](https://www.pathologyoutlines.com/topic/cdmarkerscd10.html) ([Gut Liver 2015;9:571](26343068))* [Intraductal papillary mucinous neoplasm (IPMN)](https://www.pathologyoutlines.com/topic/pancreasipmn.html)\n      + Cytokeratins ([AE1 / AE3](https://www.pathologyoutlines.com/topic/stainsae1ae3.html), [CK7](https://www.pathologyoutlines.com/topic/stainsck7.html), [CK19](https://www.pathologyoutlines.com/topic/stainsck19.html), [CAM 5.2](https://www.pathologyoutlines.com/topic/stainscam52.html)), [CEA](https://www.pathologyoutlines.com/topic/stainscea.html), [B72.3](https://www.pathologyoutlines.com/topic/stainsb723.html) and [MUC5AC](https://www.pathologyoutlines.com/topic/stainsmuc2.html#muc5ac) are positive in all types+ [MUC2](https://www.pathologyoutlines.com/topic/stainsmuc2.html), [CDX2](https://www.pathologyoutlines.com/topic/stainscdx2.html) and [CK20](https://www.pathologyoutlines.com/topic/stainsck20.html) are positive in intestinal type+ [MUC1](https://www.pathologyoutlines.com/topic/stainsema.html) is typically positive in pancreatobilliary type ([Arch Pathol Lab Med 2017;141:1330](28968161))* [Pancreatic ductal adenocarcinoma](https://www.pathologyoutlines.com/topic/pancreasductal.html)\n        + Cytokeratins ([CK7](https://www.pathologyoutlines.com/topic/stainsck7.html), [CK8](https://www.pathologyoutlines.com/topic/stainsck8.html), [CK18](https://www.pathologyoutlines.com/topic/stainsck18.html) and [CK19](https://www.pathologyoutlines.com/topic/stainsck19.html)) are consistently expressed+ Cancer markers [CEA](https://www.pathologyoutlines.com/topic/stainscea.html), [CA 19-9](https://www.pathologyoutlines.com/topic/stainsca19-9.html), [CA-125](https://www.pathologyoutlines.com/topic/stainsCA125.html), [B72.3](https://www.pathologyoutlines.com/topic/stainsb723.html), **DUPAN-2** are common+ [EMA (MUC1)](https://www.pathologyoutlines.com/topic/stainsema.html), [MUC3](https://www.pathologyoutlines.com/topic/stainsmuc2.html#muc3) and [MUC5AC](https://www.pathologyoutlines.com/topic/stainsmuc2.html#muc5ac) are typically positive+ [TP53](https://www.pathologyoutlines.com/topic/stainsp53.html) is typically positive ([Semin Diagn Pathol 2014;31:443](25441308))"
  },
  {
    "id": "mucinous-pancreatic-tumor-overview_44388_1750166974.txt-22",
    "source_document": "mucinous-pancreatic-tumor-overview_44388_1750166974.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Negative stains",
    "url": "https://www.pathologyoutlines.com/topic/pancreasmucin.html#negativestains452021",
    "clean_content": "Negative stains\n\n* **[Simple mucinous cyst / mucinous nonneoplastic cyst (MNC)](https://www.pathologyoutlines.com/topic/pancreasmucnoncyst.html)**\n  + **Trypsin**, [CEA](https://www.pathologyoutlines.com/topic/stainscea.html),\n    [synaptophysin](https://www.pathologyoutlines.com/topic/stainssynaptophysin.html),\n    [chromogranin A](https://www.pathologyoutlines.com/topic/stainschromogranin.html),\n    [calretinin](https://www.pathologyoutlines.com/topic/stainscalretinin.html),\n    [alpha inhibin](https://www.pathologyoutlines.com/topic/stainsinhibina.html),\n    [MUC1](https://www.pathologyoutlines.com/topic/stainsema.html) (35% positive),\n    [MUC2](https://www.pathologyoutlines.com/topic/stainsmuc2.html) (1% positive),\n    [PR](https://www.pathologyoutlines.com/topic/stainsprog.html) (8% positive)+ [CDX2](https://www.pathologyoutlines.com/topic/stainscdx2.html) (can be focally positive) ([Arch Pathol Lab Med 2017;141:1330](28968161), [Am J Surg Pathol 2017;41:121](27740966), [Virchows Arch 2021;479:179](33511431))* [Mucinous cystic neoplasm (MCN)](https://www.pathologyoutlines.com/topic/pancreasmcn.html)\n    + [MUC1](https://www.pathologyoutlines.com/topic/stainsema.html) (can be aberrantly expressed in invasion), [MUC2](https://www.pathologyoutlines.com/topic/stainsmuc2.html), [pVHL](https://www.pathologyoutlines.com/topic/stainsvhl.html) ([Arch Pathol Lab Med 2015;139:24](25549142))* [Intraductal papillary mucinous neoplasm (IPMN)](https://www.pathologyoutlines.com/topic/pancreasipmn.html)\n      + [MUC2](https://www.pathologyoutlines.com/topic/stainsmuc2.html) (in biliary and gastric types)+ [MUC1](https://www.pathologyoutlines.com/topic/stainsema.html) (in gastric and intestinal types) ([Front Physiol 2022;13:856803](35309060))* [Pancreatic ductal adenocarcinoma](https://www.pathologyoutlines.com/topic/pancreasductal.html)\n        + [CK20](https://www.pathologyoutlines.com/topic/stainsck20.html), [vimentin](https://www.pathologyoutlines.com/topic/stainsvimentin.html), [synaptophysin](https://www.pathologyoutlines.com/topic/stainssynaptophysin.html), [chromogranin](https://www.pathologyoutlines.com/topic/stainschromogranin.html), [MUC2](https://www.pathologyoutlines.com/topic/stainsmuc2.html)+ [pVHL](https://www.pathologyoutlines.com/topic/stainsvhl.html) (positive in reactive ducts) ([Arch Pathol Lab Med 2012;136:601](22646265), [Hum Pathol 2013;44:503](23079206))+ [SMAD4 / DPC4](https://www.pathologyoutlines.com/topic/stainsdpc4.html) loss seen in 55%; specific for malignancy ([Am J Clin Pathol 2001;116:831](11764071))"
  },
  {
    "id": "mucinous-pancreatic-tumor-overview_44388_1750166974.txt-23",
    "source_document": "mucinous-pancreatic-tumor-overview_44388_1750166974.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Molecular / cytogenetics description",
    "url": "https://www.pathologyoutlines.com/topic/pancreasmucin.html#molecularcytogeneticsdescription452024",
    "clean_content": "Molecular / cytogenetics description\n\n* Simple mucinous cyst / mucinous nonneoplastic cyst (MNC)\n  + *KMT2C* (62%), *KRAS* (15%), *TP53* (15%), *BRAF* (8%), *RNF43* (8%), *CDKN2A* (8%), *SMAD4* (8%)+ No mutations detected in 31% of cases ([Hum Pathol 2020;101:1](32380013))* Mucinous cystic neoplasm (MCN)\n    + *KRAS* (21 - 46%) and *RNF43* (~50%) mutations in low grade lesions+ Inactivating  and *TP53* mutations in more advanced MCN+ No *GNAS* mutations ([Gut Liver 2015;9:571](26343068), [Proc Natl Acad Sci U S A 2011;108:21188](22158988), [J Gastrointest Surg 2020;24:1201](32128679), [Virchows Arch 2022;480:1189](35066614))* Intraductal papillary mucinous neoplasm (IPMN)\n      + Commonly mutated: *KRAS* (90%), *GNAS* (40 - 60%), *RNF43* (25%), *TP53* (10%)+ Lower frequency: *CDKN2A*, *CTNNB1*, *IDH1*, *STK11*, *PTEN* ([World J Gastroenterol 2021;27:2710](34135550))* Pancreatic ductal adenocarcinoma\n        + Key drivers\n          - *TP53* is inactivated in 50 - 75%- *KRAS*: 70 - 95%, early event- *CDKN2A*  (p16): > 95%- *SMAD4*: ~50 - 55%- *BRCA1 / BRCA2*: 5 - 10%+ Other less common alterations: microsatellite instability (MSI), *BRAF* mutations, *MGMT* promotor hypermethylation ([Cancer Cell 2017;32:185](28810144), [World J Gastroenterol 2021;27:2710](34135550))"
  },
  {
    "id": "mucinous-pancreatic-tumor-overview_44388_1750166974.txt-24",
    "source_document": "mucinous-pancreatic-tumor-overview_44388_1750166974.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Sample pathology report",
    "url": "https://www.pathologyoutlines.com/topic/pancreasmucin.html#samplepathologyreport452027",
    "clean_content": "Sample pathology report\n\n* Distal pancreas and spleen, distal pancreatectomy and splenectomy:\n  + Intraductal papillary mucinous neoplasm (IPMN) (3.0 cm), low grade, involving branch ducts (see comment)+ Comment: Pancreatic resection margin, negative for dysplasia. No high grade dysplasia or invasive component was identified. 13 lymph nodes with reactive changes (0/13)."
  },
  {
    "id": "mucinous-pancreatic-tumor-overview_44388_1750166974.txt-25",
    "source_document": "mucinous-pancreatic-tumor-overview_44388_1750166974.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Differential diagnosis",
    "url": "https://www.pathologyoutlines.com/topic/pancreasmucin.html#differentialdiagnosis452028",
    "clean_content": "Differential diagnosis\n\n* See individual topics\n  + [Pancreatic ductal adenocarcinoma](https://www.pathologyoutlines.com/topic/pancreasductal.html#pancreasductalddx)+ [Mucinous cystic neoplasm (MCN)](https://www.pathologyoutlines.com/topic/pancreasmcn.html#pancreasmcnddx)+ [Intraductal papillary mucinous neoplasm (IPMN)](https://www.pathologyoutlines.com/topic/pancreasipmn.html#pancreasipmnddx)+ [Simple mucinous cyst / mucinous nonneoplastic cyst (MNC)](https://www.pathologyoutlines.com/topic/pancreasmucnoncyst.html#pancreasmucnoncystddx)* Also see table in [Essential features](https://www.pathologyoutlines.com/topic/pancreasmucin.html#EFsection)"
  },
  {
    "id": "mucinous-pancreatic-tumor-overview_44388_1750166974.txt-26",
    "source_document": "mucinous-pancreatic-tumor-overview_44388_1750166974.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Additional references",
    "url": "https://www.pathologyoutlines.com/topic/pancreasmucin.html#additionalreferences452029",
    "clean_content": "Additional references\n\n* [JAMA Surg 2022;157:723](35731507),  [WHO Classification of Tumours Editorial Board: Digestive System Tumours, 5th Edition, 2019](https://www.amazon.com/exec/obidos/ASIN/9283244990/pathologyoutl-20)"
  }
]